Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for biotech patents
EPO maintains ST.26 sequence listing requirement for divisionals but compromises on excess page fees EPO maintains ST.26 sequence listing requirement for divisionals but compromises on excess page fees Reviewed by Dr Rose Hughes on Friday, October 27, 2023 Rating: 5
EPO responds to criticism over ST.26 implementation EPO responds to criticism over ST.26 implementation Reviewed by Dr Rose Hughes on Tuesday, August 09, 2022 Rating: 5
EPO under fire for its approach to ST.26 sequence listings EPO under fire for its approach to ST.26 sequence listings Reviewed by Dr Rose Hughes on Monday, August 01, 2022 Rating: 5
ST. 26 sequence listings: A forward or backward step for ease of access to patent sequence data? ST. 26 sequence listings: A forward or backward step for ease of access to patent sequence data? Reviewed by Dr Rose Hughes on Sunday, February 20, 2022 Rating: 5
Is it time to rethink the patent drawing requirements? Is it time to rethink the patent drawing requirements? Reviewed by Dr Rose Hughes on Friday, January 25, 2019 Rating: 5
The ethics of biotech patenting: a dialogue about monopolies, human dignity and the cost of medicines The ethics of biotech patenting: a dialogue about monopolies, human dignity and the cost of medicines Reviewed by Suleman Ali on Sunday, January 11, 2015 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.